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Background: This study evaluated a wide range of viral load (VL)
thresholds to identify a cut-point that best predicts new clinical events
in children on stable highly active antiretroviral therapy (HAART).
Methods: Cox proportional hazards modeling was used to assess
the adjusted risk for World Health Organization stage 3 or 4 clinical
events (WHO events) as a function of time-varying CD4, VL, and
hemoglobin values in a cohort study of Latin American children on
HAART $6 months. Models were ﬁt using different VL cut-points
between 400 and 50,000 copies per milliliter, with model ﬁt evalu-
ated on the basis of the minimum Akaike information criterion value,
a standard model ﬁt statistic.
Results: Models were based on 67 subjects with WHO events out
of 550 subjects on study. The VL cut-points of .2600 and .32,000
copies per milliliter corresponded to the lowest Akaike information
criterion values and were associated with the highest hazard ratios
(2.0, P = 0.015; and 2.1, P = 0.0058, respectively) for WHO events.
Conclusions: In HIV-infected Latin American children on stable
HAART, 2 distinct VL thresholds (.2600 and .32,000 copies/mL)
were identiﬁed for predicting children at signiﬁcantly increased risk
for HIV-related clinical illness, after accounting for CD4 level,
hemoglobin level, and other signiﬁcant factors.
Key Words: pediatric HIV infection, viral load monitoring, viral
load threshold, Latin America
(J Acquir Immune Deﬁc Syndr 2012;60:214–218)
INTRODUCTION
The importance of quantitative HIV RNA, or viral load
(VL), assays for monitoring the treatment of HIV infection is
well established for adults and children and is considered
standard practice in higher-resource settings.1,2 VL before
initiation of highly active antiretroviral therapy (HAART)
has been established as an independent predictor of disease
progression in children.3–5 We previously demonstrated the
value of VL as an independent predictor of new HIV-related
World Health Organization stage 3 and 4 events (WHO
events) in a cohort of Latin American children on HAART.6
In that study, most recent VL above the 5000 copies per
milliliter level used in the WHO deﬁnition for virological
failure7 was predictive of WHO events, independent of
CD4-deﬁned immunosuppression, hemoglobin level, and
other factors; in contrast, the commonly used VL threshold
of $400 copies per milliliter was not an independent predic-
tor of WHO events in that study The present analysis used the
same data set to explore VL thresholds between 400 and
50,000 copies per milliliter to identify the cut-point for the
best-ﬁtting model for predicting new WHO events in children
on stable HAART ($6 months of continuous HAART).
METHODS
Details of the NISDI (Eunice Kennedy Shriver National
Institute of Child Health and Human Development Interna-
tional Site Development Initiative) pediatric protocol, eligibil-
ity criteria for this analysis, and methods used when applying
Cox proportional hazards modeling to assess the time to WHO
events as a function of time-varying CD4-deﬁned immunologic
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status, VL, and hemoglobin level and time-ﬁxed covariates
have been published.6
Statistical Analyses
The primary outcome measure was the ﬁrst occurrence
of a new WHO stage 3 or 4 event after the time of eligibility
for this analysis. The analyses were based on ﬁtting a pro-
portional hazards regression model to the data repeatedly,
each time using a different cut-point for the HIV-1 RNA
(VL), with VL, CD4 immunosuppression, and hemoglobin
level treated as time-varying predictors. Additional covariates
found to be independently associated with the occurrence of
WHO events in the prior publication were also included in the
modeling. The cut-point for the initial series of models was
set at 500 copy intervals for VL up to 5000 copies per
milliliter and at 5000 copy intervals for VL from 5000 to
50,000 copies per milliliter. A second series of models was ﬁt
to the data with cut-points varying by only 100 copies per
milliliter, from 2000 to 3000 copies per milliliter, and by
1000 copies per milliliter from 30,000 to 35,000 copies per
milliliter, when honing in on the best-ﬁtting model for
predicting WHO events. Model selection was based on the
Akaike information criterion (AIC), for which the model
having the minimum AIC value among competing models
represents the best ﬁt to the data.8 All analyses were con-
ducted using the SAS statistical software, version 9.0 (SAS
Institute Inc, Cary, NC).
RESULTS
The models were based on 550 subjects: 67 subjects
experienced a WHO stage 3 or 4 event during follow-up and
483 were censored (did not experience an event during
TABLE 1. Summary of Results for Fitting Proportional Hazards Regression Models for Predicting the Occurrence of WHO Events
Using Different Cut-Points for VL
VL Cut-Point AIC
VL P
HR (95% CI) P CD4 Hemoglobin
400 731.148 1.61 (0.88 to 2.96) 0.12 ,0.001 0.001
1000 730.969 1.61 (0.90 to 2.87) 0.11 ,0.001 0.001
1500 730.547 1.66 (0.94 to 2.93) 0.08 ,0.001 0.002
2000 729.547 1.78 (1.01 to 3.15) 0.047 ,0.001 0.002
2100 729.249 1.82 (1.03 to 3.22) 0.040 ,0.001 0.002
2200 728.686 1.88 (1.07 to 3.33) 0.030 ,0.001 0.002
2300 728.501 1.91 (1.08 to 3.37) 0.027 ,0.001 0.002
2400 728.218 1.94 (1.10 to 3.42) 0.023 ,0.001 0.002
2500 727.842 1.98 (1.12 to 3.50) 0.019 ,0.001 0.002
2600 727.426 2.02 (1.15 to 3.58) 0.015 ,0.001 0.002
2700 728.472 1.89 (1.08 to 3.32) 0.026 ,0.001 0.002
2800 728.214 1.92 (1.10 to 3.37) 0.023 ,0.001 0.002
2900 729.199 1.80 (1.03 to 3.14) 0.038 ,0.001 0.002
3000 729.073 1.82 (1.04 to 3.17) 0.036 ,0.001 0.002
3500 730.179 1.67 (0.97 to 2.88) 0.07 ,0.001 0.001
4000 730.218 1.66 (0.97 to 2.86) 0.07 ,0.001 0.002
4500 729.704 1.73 (1.00 to 2.97) 0.049 ,0.001 0.002
5000 729.003 1.81 (1.05 to 3.11) 0.033 0.001 0.002
7000 730.003 1.69 (0.99 to 2.88) 0.057 ,0.001 0.002
9000 730.151 1.67 (0.98 to 2.86) 0.0608 ,0.001 0.002
10,000 732.986 1.25 (0.74 to 2.13) 0.41 ,0.001 ,0.001
15,000 732.025 1.41 (0.84 to 2.39) 0.20 ,0.001 ,0.001
20,000 730.618 1.61 (0.94 to 2.73) 0.0778 ,0.001 ,0.001
25,000 729.574 1.75 (1.03 to 2.99) 0.0402 0.001 ,0.001
30,000 727.356 2.02 (1.18 to 3.45) 0.0105 0.002 0.001
31,000 726.737 2.09 (1.22 to 3.58) 0.0073 0.003 0.001
32,000 726.345 2.13 (1.25 to 3.66) 0.0058 0.003 0.001
33,000 727.481 2.02 (1.17 to 3.47) 0.0112 0.002 0.001
34,000 728.294 1.93 (1.12 to 3.32) 0.0180 0.002 0.001
35,000 727.501 2.03 (1.18 to 3.49) 0.0111 0.002 0.001
40,000 729.282 1.84 (1.06 to 3.22) 0.0318 0.001 ,0.001
45,000 730.121 1.75 (0.99 to 3.10) 0.0533 0.001 ,0.001
50,000 731.102 1.64 (0.09 to 2.94) 0.1005 ,0.001 ,0.001
Models having the minimum AIC values among competing models represent the best ﬁt to the data (indicated in bold).
WHO, World Health Organization; VL, viral load; CI, conﬁdence interval; AIC, Akaike information criterion; HR, hazard ratio; CD4, CD41 T-lymphocyte.
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follow-up); there were an additional 22 subjects with WHO
events who were excluded from the modeling due to
missing values for 1 or more covariates, with most missing
CD4 measures.
For each VL cut-point, Table 1 presents (a) the AIC
goodness-of-ﬁt measure; (b) the estimated hazard ratio (HR),
conﬁdence interval, and P value for assessing the contribution
of VL to the model; and (c) the P values for assessing the
contribution of CD4 immunosuppression and hemoglobin to
the ﬁtted model. The AIC started at a high point at the VL cut-
point of 400 copies per milliliter, declined to the ﬁrst low point
occurring at a VL cut-point of 2600 copies per milliliter before
rising again, and then declined to the second low point at a VL
cut-point of 32,000 copies per milliliter (Table 1; Fig. 1).
The HR provides an estimate of the instantaneous risk
of experiencing a WHO event associated with having a VL at
or above the speciﬁed cut-point. For example, the HR of 1.61
for the VL cut-point of 400 copies per milliliter indicates that
FIGURE 1. Akaike information crite-
rion goodness-of-fit measure plotted
as a function of HIV viral load
cut-points.
TABLE 2. Hazard Ratios for Covariates When Using VL Cutoffs of 2600 or 32,000 Copies Per Milliliter in the Model
2600 VL Cut-Point 32,000 VL Cut-Point
HR (95% CI) P HR (95% CI) P
Visits with VL , cut-point 2550 3766
Visits with VL $ cut-point 1965 749
VL 2.02 (1.15 to 3.58) 0.015 2.13 (1.25 to 3.66) 0.006
CD4 immunosuppression
Mild/advanced 2.35 (1.32 to 4.17) ,0.001 2.37 (1.33 to 4.21) 0.003
Severe 3.40 (1.69 to 6.84) 2.98 (1.44 to 6.14)
None 1.00 1.00
Hemoglobin 0.76 (0.64 to 0.91) 0.002 0.75 (0.63 to 0.89) 0.001
WHO BMI 0.001 0.004
.2 SD 0.11 (0.02 to 0.51) 0.15 (0.03 to 0.68)
Normal 0.13 (0.05 to 0.40) 0.16 (0.05 to 0.47)
,−2 SD 1.00 1.00
CDC classiﬁcation
B 2.01 (0.95 to 4.22) 0.056 1.98 (0.94 to 4.17) 0.046
C 2.41 (1.17 to 4.96) 2.49 (1.21 to 5.10)
A 1.00 1.00
Age 0.99 (0.99 to 1.00) 0.14 0.99 (0.99 to 1.00) 0.19
VL, viral load; HR, hazard ratio; CI, conﬁdence interval; CD4, CD41 T-lymphocyte; WHO, World Health Organization; WHO BMI, WHO-deﬁned body mass index CDC,
Centers for Disease Control and Prevention.
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subjects who had a VL measure at or above this cut-point
were 61% more likely to experience a WHO event as those
whose VL did not reach this level. The risk (HR) of WHO
events was higher for the VL cutoffs associated with the
lowest AIC scores (ie, best ﬁt to the data): subjects with VL at
or above the cut-point of 2600 copies per milliliter had
a 2.0-fold higher risk (HR) for WHO events compared with
those whose VL was below this level (P = 0.015); subjects
with VL at or above the cut-point of 32,000 copies per
milliliter had a 2.1 higher risk (HR) for WHO events
compared with those whose VL was below this level
(P = 0.0058). The HRs for CD4 level, HIV clinical stage,
hemoglobin level, body size, and age were very similar
when using either VL cutoff of 2600 or 32,000 copies per
milliliter in the model (Table 2).
DISCUSSION
Prior analysis of this large cohort of perinatally HIV-
infected Latin American children taking HAART for at least
6 months demonstrated that most recent VL greater than the
WHO-deﬁned virological failure threshold of 5000 copies per
milliliter —but not above the 6-month virological failure
threshold of 400 copies per milliliter used by US pediatric
treatment guidelines at the time—was an independent predic-
tor of WHO stage 3 and 4 events, even after adjusting for
most recent CD4-deﬁned immunosuppression, hemoglobin
level, and other cofactors.6 By repeatedly using the same pro-
portional hazards regression modeling with different VL cut-
offs, we were able to demonstrate that 2 distinct VL cutoffs
(2600 and 32,000 copies/mL) were the best-ﬁtting models for
predicting WHO events among VL cutoffs between 400 and
50,000 copies per milliliter.
It was somewhat expected that this analysis would yield
a VL cutoff close to the 5000 copies per milliliter threshold
reported in the original analysis. It was surprising, however,
that the search for the VL cutoff that added the most
independent value for predicting HIV-related clinical events
would also yield a second, much higher VL cutoff that had such
similar performance characteristics in the model. Furthermore,
there was no evidence that the similar performance of these 2
VL cutoffs in the model was due to compensatory differences
between the HR for CD4 level, hemoglobin level, age, and
other factors included in the model. The VL cutoff of 32,000
copies per milliliter in the present analysis is similar to the
30,000 copies per milliliter threshold used in the Paediatric
European Network for Treatment of AIDS 9/Pediatric AIDS
Clinical Trials Group 390 (PENPACT-1) study that compared
clinical and other outcomes among children randomized to
switch to a newHAART regimen at a conﬁrmedVL threshold of
1000 copies per milliliter versus at a threshold of 30,000 copies
per milliliter.9 In that PENPACT-1 study, the clinical outcomes
for children who switched at 30,000 copies per milliliter were
similar to those for childrenwho switched at the lowerVL thresh-
old. The ﬁnding in the current analysis of a maximum predictive
value for clinical events when children had VL.32,000 copies
per milliliter would be consistent with PENPACT-1 ﬁndings
showing no clinical detriment in waiting until VL of 30,000 cop-
ies per milliliter to switch therapy in children.
Other factors besides HIV-related clinical events must
also be considered when choosing a VL cutoff for treatment
failure or as a trigger to switch to a new HAART regimen in
children. In the PENPACT-1 study, there was a trend in
children on nonnucleoside reverse transcriptase inhibitor–-
based therapy who switched therapy after a VL of 30,000 cop-
ies per milliliter to accumulate more resistance mutations to the
nucleoside reverse transcriptase inhibitors in the regimen. In
contrast, there may be fewer second-line antiretroviral drugs
tested or in formulations appropriate for children, limiting
the feasibility of making a switch to a new HAART regimen
at low VL cutoffs. In resource-rich settings where virolog-
ical monitoring is routine, virological failure is suspected
when adults and children who have been on HAART for at
least 6 months have repeatedly detectable VL measurements
($50–200 copies/mL).1,2 Assays that detect such low-level
VL are unlikely to become available in low-resource set-
tings. However, quantitative RNA assays from dried blood
spots have been developed for use in low-resource settings
with detection limits that should allow for detecting chil-
dren who have VL of 30,000 copies per milliliter or even
2600 copies per milliliter.10 It will now be important to
evaluate the clinical predictive value of a broad range of
virological cutoffs using data from other cohorts of children
on stable HAART to help conﬁrm the best target for viro-
logical monitoring in pediatric HIV programs.
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